William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
William Blair on Aveanna Healthcare Holdings Inc (AVAH): 'Pullback Presents Attractive Risk/Reward'
-
William Blair on Compass Diversified (CODI): not without risks, but undervalued
-
William Blair Reiterates Outperform Rating on Chewy Inc. (CHWY) ahead of earnings
-
William Blair on Larimar Therapeutics (LRMR): not without risk but favorable risk/reward
-
Wolfspeed raises $475.9 million through convertible notes and stock sale
-
Wolfspeed Announces Subscriptions for $379 Million of Convertible Notes and $96.9 Million of Common Stock and Pre-Funded Warrants
-
William Blair on Aveanna Healthcare (AVAH) after earnings: valuation presents compelling risk/reward
-
William Blair Upgrades Five Below (FIVE) to Outperform
-
William Blair stays Outperform on CoStar Group (CSGP): Homes.com premarket expansion 'net positive'
-
William Blair Reiterates Market Perform Rating on Carlisle (CSL) amid roofing price hikes
-
William Blair stays Outperform on AAON Inc (AAON): 'pullback a buying opprotunity'
-
William Blair on Oklo (OKLO): risks to pre-rev biz, but Oklo a leader making progress under reg environment
-
William Blair on NVIDIA (NVDA): positioned to capture 'lion's share' of AI infra spend 'for years to come'
-
William Blair on Lantheus Holdings (LNTH) following PDUFA date extended: 'optimistic' co will receive approval
-
William Blair on Kalaris (KLRS) after positive data: 'blockbuster potential for TH103'
-
Mastercard deepens stablecoin push with up to $1.8 billion BVNK acquisition
-
Audax Private Equity Acquires Property Management Company AKAM
-
Nautic Partners Announces Sale of Property Management Company AKAM
-
William Blair Reiterates Outperform Rating on Structure Therapeutics (GPCR): 'considerable market opportunity for aleniglipron'
-
William Blair Reiterates Market Perform Rating on Neogenomics (NEO) following 'much-needed positive catalyst'
-
William Blair Reiterates Outperform Rating on Dianthus Therapeutics (DNTH): 'should see multiple value inflection for shares'
-
Alto Neuroscience raises $120 million in private placement financing
-
Alto Neuroscience Announces $120 Million Private Placement Financing
-
Street Calls of the Week
-
William Blair Starts Alamo Group (ALG) at Outperform
-
European shares snap three-day losing streak as oil prices retreat
-
William Blair on Fidelity National Info Services (FIS): 'Strong Set of Assets With Compelling Valuation'
-
William Blair Reiterates Outperform Rating on PAR Technology (PAR) after convertible debt offering announcement
-
William Blair Reiterates Outperform Rating on Dave Inc (DAVE): 'We recommend investors accumulate DAVE shares'
-
William Blair: 'The pace at which Carvana is growing puts it in rare air'
-
Echoes of 2022? Markets look back to Russia play book for Middle East conflict
-
Ulta Beauty slumps as rising costs hit margins, TikTok push under new CEO in focus
-
William Blair Reiterates Outperform Rating on ServiceTitan (TTAN): 'we view valuation as attractive'
-
William Blair Reiterates Market Perform Rating on El Pollo Loco (LOCO) following earnings report
-
Oxford Lane Capital Corp. Prices Preferred Stock Offering
-
Leading broker sees 'an attractive risk/reward' in this major AI chip stock
-
William Blair Downgrades PagerDuty (PD) to Market Perform
-
William Blair Reiterates Outperform Rating on VSE Corporation (VSEC): "We view today’s 7% stock drawdown as a buying opportunity"
-
Form N-CEN WILLIAM BLAIR FUNDS For: Dec 31
-
Xenon Pharmaceuticals closes $747.5 million public offering
-
Dianthus Therapeutics completes $719 million public offering
-
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
William Blair Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "entering 2026 with increasing momentum"
-
William Blair Reiterates Market Perform Rating on UiPath Inc. (PATH): "incrementally encouraged"
-
William Blair Reiterates Outperform Rating on Aveanna Healthcare Holdings Inc (AVAH) following acquisition announcement
-
Oxford Lane Capital announces preferred stock offering
-
Oxford Lane Capital Corp. Announces Preferred Stock Offering
-
William Blair: 'We like CRCL for long-term investors'
-
William Blair Reiterates Outperform Rating on AppLovin Corp (APP) following meeting with management

